VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

ChemoMetec A/S vs Edwards Lifesciences Corporation

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

Edwards Lifesciences Corporation

EW · New York Stock Exchange

Market cap (USD)$46B
Gross margin (TTM)78.1%
Operating margin (TTM)26.7%
Net margin (TTM)17.6%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-31
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Edwards Lifesciences Corporation's moat claims, evidence, and risks.

View EW analysis

Comparison highlights

  • Moat score gap: Edwards Lifesciences Corporation leads (82 / 100 vs 67 / 100 for ChemoMetec A/S).
  • Segment focus: ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing); Edwards Lifesciences Corporation has 3 segments (75.5% in Transcatheter Aortic Valve Replacement (TAVR)).
  • Moat breadth: ChemoMetec A/S has 4 moat types across 2 domains; Edwards Lifesciences Corporation has 6 across 3.

Primary market context

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

Edwards Lifesciences Corporation

Transcatheter Aortic Valve Replacement (TAVR)

Market

Transcatheter aortic valve replacement (TAVR) devices

Geography

Global

Customer

Hospitals and structural heart centers

Role

Medical device manufacturer

Revenue share

75.5%

Side-by-side metrics

ChemoMetec A/S
Edwards Lifesciences Corporation
Ticker / Exchange
CHEMM - Nasdaq Copenhagen A/S
EW - New York Stock Exchange
Market cap (USD)
n/a
$46B
Gross margin (TTM)
n/a
78.1%
Operating margin (TTM)
n/a
26.7%
Net margin (TTM)
n/a
17.6%
Sector
Healthcare
Healthcare
Industry
n/a
Medical - Devices
HQ country
DK
US
Primary segment
Life science research, cell and gene therapy, and bioprocessing
Transcatheter Aortic Valve Replacement (TAVR)
Market structure
Oligopoly
Oligopoly
Market share
15%-25% (estimated)
60%-73% (estimated)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
67 / 100
82 / 100
Moat domains
Demand, Network
Demand, Legal, Supply
Last update
2026-04-24
2025-12-31

Moat coverage

Shared moat types

Brand Trust

ChemoMetec A/S strengths

Installed Base ConsumablesDesign In QualificationInteroperability Hub

Edwards Lifesciences Corporation strengths

Training Org Change CostsRegulated Standards PipeIP Choke PointCompliance AdvantageSupply Chain Control

Segment mix

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

Edwards Lifesciences Corporation segments

Full profile >

Transcatheter Aortic Valve Replacement (TAVR)

Oligopoly

75.5%

Transcatheter Mitral and Tricuspid Therapies (TMTT)

Competitive

6.5%

Surgical Structural Heart

Oligopoly

18%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.